Package | us.nlm.vsac |
Type | ValueSet |
Id | Id |
FHIR Version | R4 |
Source | http://fhir.org/packages/us.nlm.vsac/https://vsac.nlm.nih.gov/valueset/2.16.840.1.113762.1.4.1196.4469/expansion |
Url | http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469 |
Version | 20240515 |
Status | active |
Date | 2024-05-15T01:01:25-04:00 |
Name | CabotegravirInjectableProducts |
Title | Cabotegravir Injectable Products |
Experimental | False |
Realm | us |
Authority | hl7 |
Description | Under Cooperative Agreement number 6-NU38OT000316, funded by the CDC Division of Sexually Transmitted Disease Prevention and the Division of HIV Prevention, the Public Health Informatics Institute coordinated a project to test the feasibility, usability and acceptance of a CDS solution aimed at increasing adherence to public health guidelines for treating gonorrhea, encouraging human immunodeficiency virus screening and raising awareness of pre-exposure prophylaxis prescriptions in clinical settings. See https://phii.org/sti-connect-cds/ for full information. This value set was created to support that work and could be used to inform the development of a similar solution in a clinical environment. It is important to note that the CDS solution incorporated portions of public health guidelines for GC treatment, HIV screening and PrEP education and does not reflect a full implementation of the guidelines. |
Purpose | (Clinical Focus: GPCK & BPCKs were added manually by finding codes in RxNav),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: ) |
No resources found
CodeSystem | |
http://www.nlm.nih.gov/research/umls/rxnorm | RxNorm |
http://www.nlm.nih.gov/research/umls/rxnorm | RxNorm |
{
"resourceType" : "ValueSet",
"id" : "2.16.840.1.113762.1.4.1196.4469",
"meta" : {
"versionId" : "10",
"lastUpdated" : "2024-07-29T08:54:37.000-04:00",
"profile" : [
"http://hl7.org/fhir/StructureDefinition/shareablevalueset",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm",
"http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
]
},
"extension" : [
{
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
"valueContactDetail" : {
"name" : "CDC DHP TEB Author"
}
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
"valueDate" : "2024-05-15"
},
{
"url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
"valueDate" : "2024-05-15"
}
],
"url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1196.4469",
"identifier" : [
{
"system" : "urn:ietf:rfc:3986",
"value" : "urn:oid:2.16.840.1.113762.1.4.1196.4469"
}
],
"version" : "20240515",
"name" : "CabotegravirInjectableProducts",
"title" : "Cabotegravir Injectable Products",
"status" : "active",
"date" : "2024-05-15T01:01:25-04:00",
"publisher" : "CDC DHP TEB Steward",
"description" : "Under Cooperative Agreement number 6-NU38OT000316, funded by the CDC Division of Sexually Transmitted Disease Prevention and the Division of HIV Prevention, the Public Health Informatics Institute coordinated a project to test the feasibility, usability and acceptance of a CDS solution aimed at increasing adherence to public health guidelines for treating gonorrhea, encouraging human immunodeficiency virus screening and raising awareness of pre-exposure prophylaxis prescriptions in clinical settings. See https://phii.org/sti-connect-cds/ for full information. This value set was created to support that work and could be used to inform the development of a similar solution in a clinical environment. It is important to note that the CDS solution incorporated portions of public health guidelines for GC treatment, HIV screening and PrEP education and does not reflect a full implementation of the guidelines.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "US"
}
]
}
],
"purpose" : "(Clinical Focus: GPCK & BPCKs were added manually by finding codes in RxNav),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )",
"compose" : {
"include" : [
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"concept" : [
{
"code" : "2475408",
"display" : "cabotegravir Injectable Product"
},
{
"code" : "2475415",
"display" : "{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack"
},
{
"code" : "2475416",
"display" : "{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 600 MG / 900 MG]"
},
{
"code" : "2475417",
"display" : "{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack"
},
{
"code" : "2475418",
"display" : "{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 400 MG / 600 MG]"
},
{
"code" : "2588046",
"display" : "Apretude Injectable Product"
},
{
"code" : "2588076",
"display" : "cabotegravir Injection"
},
{
"code" : "2588077",
"display" : "3 ML cabotegravir 200 MG/ML Injection"
},
{
"code" : "2588078",
"display" : "cabotegravir 200 MG/ML Injection"
},
{
"code" : "2588079",
"display" : "cabotegravir Injection [Apretude]"
},
{
"code" : "2588080",
"display" : "3 ML cabotegravir 200 MG/ML Injection [Apretude]"
},
{
"code" : "2588081",
"display" : "cabotegravir 200 MG/ML Injection [Apretude]"
},
{
"code" : "2594978",
"display" : "2 ML cabotegravir 200 MG/ML Injection"
}
]
}
]
},
"expansion" : {
"identifier" : "urn:uuid:70ffe7ad-22fa-4ace-be40-e489931c62fb",
"timestamp" : "2024-12-10T07:37:31-05:00",
"total" : 11,
"contains" : [
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2475408",
"display" : "cabotegravir Injectable Product"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2475415",
"display" : "{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2475416",
"display" : "{1 (3 ML cabotegravir 200 MG/ML Injection) / 1 (3 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 600 MG / 900 MG]"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2475417",
"display" : "{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2475418",
"display" : "{1 (2 ML cabotegravir 200 MG/ML Injection) / 1 (2 ML rilpivirine 300 MG/ML Injection) } Pack [CABENUVA 400 MG / 600 MG]"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2588046",
"display" : "Apretude Injectable Product"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2588076",
"display" : "cabotegravir Injection"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2588077",
"display" : "3 ML cabotegravir 200 MG/ML Injection"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2588079",
"display" : "cabotegravir Injection [Apretude]"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2588080",
"display" : "3 ML cabotegravir 200 MG/ML Injection [Apretude]"
},
{
"system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
"version" : "11042024",
"code" : "2594978",
"display" : "2 ML cabotegravir 200 MG/ML Injection"
}
]
},
"text" : {
}
}
XIG built as of ??metadata-date??. Found ??metadata-resources?? resources in ??metadata-packages?? packages.